The Supreme Court has disempowered public health agencies and devalued science, raising concerns about the future of public health in the United States. This decision is linked to the Braidwood Management Inc v Becerra case, which involves conflicts between the intent of Congress, public health, and the law, and poses risks to the USPSTF. Additionally, the FDA's new mandate for diversity action plans in clinical trials has sparked debate over whether focusing on enrollment quotas could lead to tokenistic efforts. Experts, including Gregory Curfman, argue that modern medicine should rely on good scientific studies rather than medical dogma.